Cargando…

Hepatopathy following consumption of a commercially available blue-green algae dietary supplement in a dog

BACKGROUND: Dietary supplement use in both human and animals to augment overall health continues to increase and represents a potential health risk due to the lack of safety regulations imposed on the manufacturers. Because there are no requirements for demonstrating safety and efficacy prior to mar...

Descripción completa

Detalles Bibliográficos
Autores principales: Bautista, Adrienne C., Moore, Caroline E., Lin, Yanping, Cline, Martha G., Benitah, Noemi, Puschner, Birgit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472392/
https://www.ncbi.nlm.nih.gov/pubmed/26087767
http://dx.doi.org/10.1186/s12917-015-0453-2
_version_ 1782377048636915712
author Bautista, Adrienne C.
Moore, Caroline E.
Lin, Yanping
Cline, Martha G.
Benitah, Noemi
Puschner, Birgit
author_facet Bautista, Adrienne C.
Moore, Caroline E.
Lin, Yanping
Cline, Martha G.
Benitah, Noemi
Puschner, Birgit
author_sort Bautista, Adrienne C.
collection PubMed
description BACKGROUND: Dietary supplement use in both human and animals to augment overall health continues to increase and represents a potential health risk due to the lack of safety regulations imposed on the manufacturers. Because there are no requirements for demonstrating safety and efficacy prior to marketing, dietary supplements may contain potentially toxic contaminants such as hepatotoxic microcystins produced by several species of blue-green algae. CASE PRESENTATION: An 11-year-old female spayed 8.95 kg Pug dog was initially presented for poor appetite, lethargy polyuria, polydipsia, and an inability to get comfortable. Markedly increased liver enzyme activities were detected with no corresponding abnormalities evident on abdominal ultrasound. A few days later the liver enzyme activities were persistently increased and the dog was coagulopathic indicating substantial liver dysfunction. The dog was hospitalized for further care consisting of oral S-adenosylmethionine, silybin, vitamin K, and ursodeoxycholic acid, as well as intravenous ampicillin sodium/sulbactam sodium, dolasetron, N-acetylcysteine, metoclopramide, and intravenous fluids. Improvement of the hepatopathy and the dog’s clinical status was noted over the next three days. Assessment of the dog’s diet revealed the use of a commercially available blue-green algae dietary supplement for three-and-a-half weeks prior to hospitalization. The supplement was submitted for toxicology testing and revealed the presence of hepatotoxic microcystins (MCs), MC-LR and MC-LA. Use of the supplement was discontinued and follow-up evaluation over the next few weeks revealed a complete resolution of the hepatopathy. CONCLUSIONS: To the authors’ knowledge, this is the first case report of microcystin intoxication in a dog after using a commercially available blue-green algae dietary supplement. Veterinarians should recognize the potential harm that these supplements may cause and know that with intervention, recovery is possible. In addition, more prudent oversight of dietary supplement use is recommended for our companion animals to prevent adverse events/intoxications.
format Online
Article
Text
id pubmed-4472392
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44723922015-06-19 Hepatopathy following consumption of a commercially available blue-green algae dietary supplement in a dog Bautista, Adrienne C. Moore, Caroline E. Lin, Yanping Cline, Martha G. Benitah, Noemi Puschner, Birgit BMC Vet Res Case Report BACKGROUND: Dietary supplement use in both human and animals to augment overall health continues to increase and represents a potential health risk due to the lack of safety regulations imposed on the manufacturers. Because there are no requirements for demonstrating safety and efficacy prior to marketing, dietary supplements may contain potentially toxic contaminants such as hepatotoxic microcystins produced by several species of blue-green algae. CASE PRESENTATION: An 11-year-old female spayed 8.95 kg Pug dog was initially presented for poor appetite, lethargy polyuria, polydipsia, and an inability to get comfortable. Markedly increased liver enzyme activities were detected with no corresponding abnormalities evident on abdominal ultrasound. A few days later the liver enzyme activities were persistently increased and the dog was coagulopathic indicating substantial liver dysfunction. The dog was hospitalized for further care consisting of oral S-adenosylmethionine, silybin, vitamin K, and ursodeoxycholic acid, as well as intravenous ampicillin sodium/sulbactam sodium, dolasetron, N-acetylcysteine, metoclopramide, and intravenous fluids. Improvement of the hepatopathy and the dog’s clinical status was noted over the next three days. Assessment of the dog’s diet revealed the use of a commercially available blue-green algae dietary supplement for three-and-a-half weeks prior to hospitalization. The supplement was submitted for toxicology testing and revealed the presence of hepatotoxic microcystins (MCs), MC-LR and MC-LA. Use of the supplement was discontinued and follow-up evaluation over the next few weeks revealed a complete resolution of the hepatopathy. CONCLUSIONS: To the authors’ knowledge, this is the first case report of microcystin intoxication in a dog after using a commercially available blue-green algae dietary supplement. Veterinarians should recognize the potential harm that these supplements may cause and know that with intervention, recovery is possible. In addition, more prudent oversight of dietary supplement use is recommended for our companion animals to prevent adverse events/intoxications. BioMed Central 2015-06-19 /pmc/articles/PMC4472392/ /pubmed/26087767 http://dx.doi.org/10.1186/s12917-015-0453-2 Text en © Bautista et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Bautista, Adrienne C.
Moore, Caroline E.
Lin, Yanping
Cline, Martha G.
Benitah, Noemi
Puschner, Birgit
Hepatopathy following consumption of a commercially available blue-green algae dietary supplement in a dog
title Hepatopathy following consumption of a commercially available blue-green algae dietary supplement in a dog
title_full Hepatopathy following consumption of a commercially available blue-green algae dietary supplement in a dog
title_fullStr Hepatopathy following consumption of a commercially available blue-green algae dietary supplement in a dog
title_full_unstemmed Hepatopathy following consumption of a commercially available blue-green algae dietary supplement in a dog
title_short Hepatopathy following consumption of a commercially available blue-green algae dietary supplement in a dog
title_sort hepatopathy following consumption of a commercially available blue-green algae dietary supplement in a dog
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472392/
https://www.ncbi.nlm.nih.gov/pubmed/26087767
http://dx.doi.org/10.1186/s12917-015-0453-2
work_keys_str_mv AT bautistaadriennec hepatopathyfollowingconsumptionofacommerciallyavailablebluegreenalgaedietarysupplementinadog
AT moorecarolinee hepatopathyfollowingconsumptionofacommerciallyavailablebluegreenalgaedietarysupplementinadog
AT linyanping hepatopathyfollowingconsumptionofacommerciallyavailablebluegreenalgaedietarysupplementinadog
AT clinemarthag hepatopathyfollowingconsumptionofacommerciallyavailablebluegreenalgaedietarysupplementinadog
AT benitahnoemi hepatopathyfollowingconsumptionofacommerciallyavailablebluegreenalgaedietarysupplementinadog
AT puschnerbirgit hepatopathyfollowingconsumptionofacommerciallyavailablebluegreenalgaedietarysupplementinadog